We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+23.96%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$283M
AUM Growth
+$33.2M
Cap. Flow
+$6.04M
Cap. Flow %
2.13%
Top 10 Hldgs %
59.75%
Holding
54
New
16
Increased
6
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
WHWK
Whitehawk Therapeutics
WHWK
+$46.6M
2
BLU
BELLUS Health Inc.
BLU
+$7.61M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.3M
4
GHRS icon
GH Research
GHRS
+$4.95M
5
KRYS icon
Krystal Biotech
KRYS
+$4.29M

Top Sells

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$30.5M
2
EPIX
ESSA Pharma
EPIX
+$6.65M
3
FULC icon
Fulcrum Therapeutics
FULC
+$5.34M
4
APLS
Apellis Pharmaceuticals
APLS
+$4.78M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 93.66%
2 Financials 4.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WHWK
1
Whitehawk Therapeutics
WHWK
$196M
$44.9M 15.85%
+1,529,402
New +$46.6M
VTGN icon
2
VistaGen Therapeutics
VTGN
$10.1M
$32.1M 11.34%
390,934
– –
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$18.4M 6.5%
1,135,000
-115,000
-9% -$1.25M
CLDX icon
4
Celldex Therapeutics
CLDX
$2.96B
$18.2M 6.43%
337,500
-649,906
-66% -$30.5M
BLU
5
DELISTED
BELLUS Health Inc.
BLU
$12.3M 4.35%
+2,007,500
New +$7.61M
IOVA icon
6
Iovance Biotherapeutics
IOVA
$1.93B
$9.23M 3.26%
374,495
+225,000
+151% +$5.3M
FULC icon
7
Fulcrum Therapeutics
FULC
$283M
$9.1M 3.21%
322,500
-281,574
-47% -$5.34M
GHRS icon
8
GH Research
GHRS
$1.93B
$8.68M 3.06%
393,250
+243,250
+162% +$4.95M
BLSA
9
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$8.4M 2.96%
843,122
– –
CLSD
10
DELISTED
Clearside Biomedical
CLSD
$7.9M 2.79%
87,751
– –
ARWR icon
11
Arrowhead Research
ARWR
$12.1B
$7.58M 2.68%
121,500
+13,500
+13% +$874K
SEEL
12
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$6.89M 2.43%
745
– –
CYT
13
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$6.88M 2.43%
391,974
+114,197
+41% +$2.13M
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.02B
$6.38M 2.25%
417,409
– –
VSTM icon
15
Verastem
VSTM
$500M
$6.22M 2.19%
168,203
– –
JYAC
16
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$5.48M 1.93%
562,500
– –
KURA icon
17
Kura Oncology
KURA
$816M
$5.47M 1.93%
291,884
-61,514
-17% -$1.16M
RNAC icon
18
Cartesian Therapeutics
RNAC
$231M
$4.26M 1.5%
34,156
– –
VINC
19
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$4.2M 1.48%
13,000
-10,920
-46% -$3.19M
OLMA icon
20
Olema Pharmaceuticals
OLMA
$985M
$4.15M 1.46%
+150,500
New +$4.06M
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.7B
$3.94M 1.39%
206,126
– –
OBIO icon
22
Orchestra BioMed
OBIO
$247M
$3.88M 1.37%
392,500
– –
EYPT icon
23
EyePoint Inc
EYPT
$1.04B
$3.85M 1.36%
369,863
– –
KRYS icon
24
Krystal Biotech
KRYS
$9.21B
$3.79M 1.34%
+72,551
New +$4.29M
CABA icon
25
Cabaletta Bio
CABA
$439M
$3.68M 1.3%
+302,926
New +$2.79M
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Acuta Capital Partners held 54 positions worth $283M, up 13% from $250M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners's Q3 2021 filing shows 16 new, 6 increased, 10 reduced and 7 closed positions. Its largest new stake was Whitehawk Therapeutics: 1,529,402 shares worth $44.9M. The largest sale was Celldex Therapeutics, an estimated $30.5M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 87% a quarter earlier, followed by Financials.

  • Acuta Capital Partners's largest Q3 2021 buy was Whitehawk Therapeutics: 1,529,402 shares worth $44.9M.
  • Acuta Capital Partners added most to Iovance Biotherapeutics in Q3 2021, an estimated $5.3M increase.
  • Acuta Capital Partners's biggest Q3 2021 reduction was Celldex Therapeutics, cutting an estimated $30.5M.
  • Acuta Capital Partners fully exited ESSA Pharma in Q3 2021, selling an estimated $6.65M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $283M portfolio in Q3 2021.
  • Acuta Capital Partners opened 16 new positions and closed 7 in Q3 2021.
  • Acuta Capital Partners's portfolio value rose 13% quarter-over-quarter to $283M.

Based on Acuta Capital Partners's 13F filing for Q3 2021, filed 15 Nov 2021.